ENGN
NASDAQenGene Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.76-0.01 (-0.56%)
01:30 PM03:45 PM
News · 26 weeks51-73%
2025-12-212026-06-14
Mix2290d
- Analyst9(41%)
- SEC Filings6(27%)
- Other5(23%)
- Earnings2(9%)
Latest news
25 items- SECSEC Form 10-Q filed by enGene Therapeutics Inc.10-Q - enGene Therapeutics Inc. (0001980845) (Filer)
- SECenGene Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - enGene Therapeutics Inc. (0001980845) (Filer)
- PRenGene Reports Second Quarter 2026 Financial Results and Provides Business Update12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First patients enrolled in surfactant plus detalimogene cohort Approximately 50% reduction in force to streamline operations and preserve cash to focus on BLA and precommercial activities Well capitalized with cash, cash equivalents and marketable securities of $285 million enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and pr
- SECenGene Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - enGene Therapeutics Inc. (0001980845) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.SCHEDULE 13G/A - enGene Therapeutics Inc. (0001980845) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.SCHEDULE 13G/A - enGene Therapeutics Inc. (0001980845) (Subject)
- SECSEC Form SCHEDULE 13G filed by enGene Therapeutics Inc.SCHEDULE 13G - enGene Therapeutics Inc. (0001980845) (Subject)
- SECSEC Form DEF 14A filed by enGene Therapeutics Inc.DEF 14A - enGene Therapeutics Inc. (0001980845) (Filer)
- ANALYSTenGene Therapeutics downgraded by Raymond James with a new price targetRaymond James downgraded enGene Therapeutics from Strong Buy to Outperform and set a new price target of $4.00
- ANALYSTenGene Therapeutics downgraded by Piper Sandler with a new price targetPiper Sandler downgraded enGene Therapeutics from Overweight to Neutral and set a new price target of $4.00
- ANALYSTenGene Therapeutics downgraded by GuggenheimGuggenheim downgraded enGene Therapeutics from Buy to Neutral
- ANALYSTenGene Therapeutics downgraded by CitizensCitizens downgraded enGene Therapeutics from Mkt Outperform to Mkt Perform
- ANALYSTenGene Therapeutics downgraded by Leerink Partners with a new price targetLeerink Partners downgraded enGene Therapeutics from Outperform to Market Perform and set a new price target of $2.00
- ANALYSTenGene Therapeutics downgraded by Wells Fargo with a new price targetWells Fargo downgraded enGene Therapeutics from Overweight to Equal Weight and set a new price target of $2.00
- ANALYSTenGene Therapeutics downgraded by Morgan StanleyMorgan Stanley downgraded enGene Therapeutics from Overweight to Equal-Weight
- ANALYSTenGene Therapeutics downgraded by OppenheimerOppenheimer downgraded enGene Therapeutics from Outperform to Perform
- SECenGene Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events8-K - enGene Therapeutics Inc. (0001980845) (Filer)
- PRenGene Announces Updated Interim Results From LEGEND Pivotal Cohort54% complete response (CR) rate at any time; 43% six‑month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%) Kaplan-Meier estimate of 12-month CR rate is 25% enGene to host webcast to discuss results today, May 7, 2026, at 8:00 a.m. ET enGene Therapeutics Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND t
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.SCHEDULE 13G/A - enGene Therapeutics Inc. (0001980845) (Subject)
- ANALYSTWBB Securities initiated coverage on enGene Therapeutics with a new price targetWBB Securities initiated coverage of enGene Therapeutics with a rating of Buy and set a new price target of $21.50
- SECenGene Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - enGene Therapeutics Inc. (0001980845) (Filer)
- PRCombination Therapies Reshape Oncology: A $748B Market Shifts Standard of CareIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ
- SECSEC Form S-8 filed by enGene Holdings Inc.S-8 - enGene Holdings Inc. (0001980845) (Filer)
- SECSEC Form 424B5 filed by enGene Holdings Inc.424B5 - enGene Holdings Inc. (0001980845) (Filer)
- SECenGene Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement8-K - enGene Holdings Inc. (0001980845) (Filer)
ENGN FAQ
5 questionsWhere does ENGN stock trade?
enGene Therapeutics Inc. (ENGN) is listed on NASDAQ.What sector and industry is ENGN in?
enGene Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about ENGN?
enGene Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Outperform with a $400.00 price target on 2026-05-08. Recent price targets range from $200.00 to $400.00.What companies are similar to ENGN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ENGN side-by-side with any of them on Quantisnow.How can I track ENGN on Quantisnow?
Quantisnow aggregates enGene Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENGN to receive live email and push alerts on every new disclosure.